Polar Capital Holdings Plc Decreases Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Polar Capital Holdings Plc reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 42.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,565,831 shares of the biopharmaceutical company’s stock after selling 1,155,046 shares during the period. Polar Capital Holdings Plc’s holdings in Celldex Therapeutics were worth $39,569,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Barclays PLC raised its position in shares of Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock valued at $4,431,000 after buying an additional 76,207 shares during the last quarter. Mirador Capital Partners LP grew its position in shares of Celldex Therapeutics by 2.9% in the fourth quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company’s stock valued at $3,020,000 after purchasing an additional 3,345 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Celldex Therapeutics by 24.4% in the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 4,967 shares during the last quarter. KBC Group NV increased its holdings in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,647 shares during the last quarter. Finally, Sovran Advisors LLC purchased a new position in Celldex Therapeutics during the fourth quarter worth approximately $2,867,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. UBS Group lowered their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Morgan Stanley cut their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, Canaccord Genuity Group started coverage on Celldex Therapeutics in a research report on Monday, April 28th. They issued a “buy” rating and a $64.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.90.

Celldex Therapeutics Stock Down 3.5%

Shares of NASDAQ CLDX opened at $18.94 on Thursday. The business’s 50 day moving average is $18.90 and its two-hundred day moving average is $22.70. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -7.37 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.